Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
50 participants
INTERVENTIONAL
2016-10-31
2023-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Stellate Ganglion Block With Lidocaine Combined Platelet-rich Plasma to Treat Chronic Migraine
NCT06653218
Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale
NCT05546320
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention
NCT03238781
Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine
NCT04946734
A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
NCT00109083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
clopidogrel
clopidogrel tablet 75mg daily for three months
clopidogrel
clopidogrel troche 75 mg daily for three months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
clopidogrel
clopidogrel troche 75 mg daily for three months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* experience a minimum of two migraine attacks per month in a 3-month baseline phase
* without regular use of prophylactic treatments or unresponsive to two and more commonly applied preventive medications
* the presence of RLS confirmed by contrast-enhanced transcranial Doppler
* no positive findings in cranial CT and MRI
Exclusion Criteria
* systemic chronic diseases, cerebrovascular disease, abnormal platelet or liver function
* history of head injury
* other contraindications to clopidogrel treatment
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital Xi'an Jiaotong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guogang Luo, doctor
Role: PRINCIPAL_INVESTIGATOR
First Affiliated Hospital Xi'an Jiaotong University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XJTU1AF-CRS-2016-019
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.